CNS Pharma's Cancer Drug Misses Survival Goal But May Offer Fewer Side Effects
CNS Pharmaceuticals' Berubicin trial results show a favorable safety profile with no cardiotoxicity and comparable efficacy ...
Interesting Engineering on MSN2d
New hope for UTI patients as FDA approves first-of-its-kind antibiotic in 30 years
The U.S. Food and Drug Administration (FDA) has approved a new class of antibiotics for treating uncomplicated urinary tract ...
BioWorld15d
Charles University and MFMER divulge new DNA topoisomerase II β inhibitors to treat cardiotoxicity
Scientists at Charles University and Mayo Foundation for Medical Education and Research (MFMER) have synthesized DNA topoisomerase II β inhibitors reported to be useful for the treatment of ...
MedPage Today on MSN3d
FDA OKs New Option for Uncomplicated UTIs in Women, Girls
The FDA approved oral gepotidacin (Blujepa) for uncomplicated urinary tract infections (UTIs) in women and girls ages 12 ...
Monthly Prescribing Reference12y
Ciprofloxacin Iv Concentrate
The bactericidal action of ciprofloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV (both Type II topoisomerases), which are required for bacterial ...